[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO932442D0 - Anvendelse av 1,3-oksatiolannukleosidanaloger ved behandling av hepatitt b - Google Patents

Anvendelse av 1,3-oksatiolannukleosidanaloger ved behandling av hepatitt b

Info

Publication number
NO932442D0
NO932442D0 NO1993932442A NO932442A NO932442D0 NO 932442 D0 NO932442 D0 NO 932442D0 NO 1993932442 A NO1993932442 A NO 1993932442A NO 932442 A NO932442 A NO 932442A NO 932442 D0 NO932442 D0 NO 932442D0
Authority
NO
Norway
Prior art keywords
treatment
oxatiolanucleoside
hepatite
analogs
hepatitis
Prior art date
Application number
NO1993932442A
Other languages
English (en)
Other versions
NO180407C (no
NO180407B (no
NO932442L (no
Inventor
Bernard Belleau
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO932442(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919100039A external-priority patent/GB9100039D0/en
Priority claimed from GB919109913A external-priority patent/GB9109913D0/en
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of NO932442D0 publication Critical patent/NO932442D0/no
Publication of NO932442L publication Critical patent/NO932442L/no
Publication of NO180407B publication Critical patent/NO180407B/no
Publication of NO180407C publication Critical patent/NO180407C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO932442A 1991-01-03 1993-07-05 Anvendelse av 1,3-oksatiolannukleosidanaloger ved fremstilling av et medikament for behandling av hepatitt B NO180407C (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919100039A GB9100039D0 (en) 1991-01-03 1991-01-03 Medicaments
GB919109913A GB9109913D0 (en) 1991-05-07 1991-05-07 Medicaments
PCT/CA1992/000001 WO1992011852A1 (en) 1991-01-03 1992-01-03 Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis b

Publications (4)

Publication Number Publication Date
NO932442D0 true NO932442D0 (no) 1993-07-05
NO932442L NO932442L (no) 1993-08-26
NO180407B NO180407B (no) 1997-01-06
NO180407C NO180407C (no) 1997-04-16

Family

ID=26298202

Family Applications (1)

Application Number Title Priority Date Filing Date
NO932442A NO180407C (no) 1991-01-03 1993-07-05 Anvendelse av 1,3-oksatiolannukleosidanaloger ved fremstilling av et medikament for behandling av hepatitt B

Country Status (23)

Country Link
US (2) US5532246A (no)
EP (2) EP0565549B1 (no)
JP (1) JP2659863B2 (no)
KR (1) KR0156747B1 (no)
AT (1) ATE120644T1 (no)
AU (1) AU660650B2 (no)
CA (2) CA2100269C (no)
CY (1) CY2047B1 (no)
DE (1) DE69201948T2 (no)
DK (1) DK0565549T3 (no)
EE (1) EE02995B1 (no)
ES (1) ES2070628T3 (no)
GE (1) GEP19981482B (no)
GR (1) GR3015694T3 (no)
HK (1) HK159395A (no)
IE (1) IE73642B1 (no)
IL (1) IL100502A (no)
MD (1) MD1224C2 (no)
NO (1) NO180407C (no)
PH (1) PH31397A (no)
TJ (1) TJ249B (no)
TW (1) TW202385B (no)
WO (1) WO1992011852A1 (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
US5932635A (en) * 1991-07-30 1999-08-03 Cytec Technology Corp. Tackified prepreg systems
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
AU7954694A (en) 1993-09-10 1995-03-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
EP0869953A1 (en) * 1994-10-22 1998-10-14 Chong Kun Dang Corp Nucleoside derivatives and process for preparing thereof
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
JP4413996B2 (ja) 1995-06-07 2010-02-10 エモリー・ユニバーシティ 抗ｂ型肝炎ウィルス活性を有するヌクレオシド
GB9517022D0 (en) * 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
GB9605293D0 (en) * 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments
DE69727240T2 (de) 1996-06-25 2004-11-25 Glaxo Group Ltd., Greenford Kombinationen, enthaltend VX478, Zidovudin und 3TC zur Behandlung von HIV
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
US6410546B1 (en) 1997-04-07 2002-06-25 Triangle Pharmaceuticals, Inc. Use of MKC-442 in combination with other antiviral agents
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
WO2000009531A2 (en) 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
AU1810600A (en) 1998-11-02 2000-05-22 Triangle Pharmaceuticals, Inc. Combination therapy to treat hepatitis b virus
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
AP2006003708A0 (en) 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
WO2002070518A1 (en) 2001-03-01 2002-09-12 Triangle Pharmaceuticals, Inc. Polymorphic and other crystalline forms of cis-ftc
RS113904A (en) 2002-06-28 2007-02-05 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
WO2004024095A2 (en) 2002-09-13 2004-03-25 Idenix (Cayman) Limited ß-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
EP1976382B1 (en) 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP2435052B1 (en) 2009-05-27 2015-07-15 Hetero Research Foundation Solid oral dosage forms of lamivudine with isomalt

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07116042B2 (ja) * 1985-05-15 1995-12-13 ザ ウエルカム フアウンデ−シヨン リミテツド ヌクレオシド化合物
US5039667A (en) * 1987-08-07 1991-08-13 The Governors Of The University Of Alberta Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
CA1327000C (en) * 1987-08-07 1994-02-15 David L.J. Tyrrell Antiviral therapy for hepatitis b
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
JP2578501B2 (ja) * 1989-03-03 1997-02-05 キヤノン株式会社 電子写真用帯電部材
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
JPH04501854A (ja) * 1989-05-15 1992-04-02 アメリカ合衆国 肝炎の治療方法
JPH04501857A (ja) * 1989-05-15 1992-04-02 アメリカ合衆国 肝炎の治療方法
WO1991000282A1 (en) * 1989-06-27 1991-01-10 The Wellcome Foundation Limited Therapeutic nucleosides
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
KR910007655A (ko) * 1989-10-03 1991-05-30 엠. 피. 잭슨 치료용 뉴클레오시드
IE74701B1 (en) * 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
PT95516A (pt) * 1989-10-06 1991-08-14 Wellcome Found Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ES2091948T3 (es) * 1990-11-13 1996-11-16 Iaf Biochem Int 1,3-oxatiolanos sustituidos con propiedades antiviricas.
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
DK0574487T3 (da) * 1991-03-06 2002-10-14 Univ Emory Anvendelse af 5-fluor-2'-deoxy-thiacytidin til behandling af hepatitis B
GB9105899D0 (en) * 1991-03-20 1991-05-08 Wellcome Found Therapeutic nucleosides
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments

Also Published As

Publication number Publication date
KR0156747B1 (en) 1998-11-16
USRE39155E1 (en) 2006-07-04
JPH06507150A (ja) 1994-08-11
US5532246A (en) 1996-07-02
EP0494119A1 (en) 1992-07-08
CY2047B1 (en) 1998-04-30
AU660650B2 (en) 1995-07-06
DK0565549T3 (da) 1995-07-03
TW202385B (no) 1993-03-21
WO1992011852A1 (en) 1992-07-23
EP0565549A1 (en) 1993-10-20
IL100502A0 (en) 1992-09-06
GEP19981482B (en) 1998-12-25
JP2659863B2 (ja) 1997-09-30
AU1153492A (en) 1992-08-17
MD1224C2 (ro) 1999-11-30
PH31397A (en) 1998-10-29
IL100502A (en) 1995-12-08
GR3015694T3 (en) 1995-07-31
HK159395A (en) 1995-10-20
CA2254613A1 (en) 1992-07-04
NO180407C (no) 1997-04-16
MD950086A (ro) 1997-01-31
EP0565549B1 (en) 1995-04-05
CA2100269A1 (en) 1992-07-04
NO180407B (no) 1997-01-06
ATE120644T1 (de) 1995-04-15
NO932442L (no) 1993-08-26
MD1224B2 (en) 1999-05-31
CA2100269C (en) 1999-02-23
DE69201948T2 (de) 1995-08-03
TJ249B (en) 1999-12-23
DE69201948D1 (de) 1995-05-11
IE73642B1 (en) 1997-06-18
IE920004A1 (en) 1992-07-15
EE02995B1 (et) 1997-06-16
ES2070628T3 (es) 1995-06-01

Similar Documents

Publication Publication Date Title
NO932442L (no) Anvendelse av 1,3-oksatiolannukleosidanaloger ved behandling av hepatitt b
HUT59109A (en) Process for producing hydroxymethyl-(methylenecyclopentyl)-purines and -pyrimidines, their pharmaceutically acceptable salts and pharmaceutical compositions comprising same
NO174711C (no) Analogifremgangsmåte for fremstilling av nye, terapeutisk aktive pyrimidindionderivater
HK62797A (en) A pharmaceutical solution comprising derivatives of FK506
DK132188A (da) Anvendelse af tetrahydrobenz(c,d)indol-6-carboxamider som anxiolytika
IL88740A0 (en) Compositions for the inhibition of viruses
FI911138A0 (fi) Ny substituerad aminfoerening och foerfarande foer dess framstaellning.
ES2073871T3 (es) Tiazolidin-2,4-dionas en el tratamiento de la hipertension.
DK0784973T3 (da) Quinoxalinderivater til behandling af tinnitus
TW275629B (no)
DE3867494D1 (de) Fluor enthaltende vitamin-d2-derivate.
FI933928A (fi) Heteroarenylpiperaziner, foerfarande foer framstaellning av dessa och anvaendning som laekemedel
ATE106727T1 (de) Verwendung eines benzo(b>thiophen-2- carboximidamid-derivates gegen herzinsuffizienz.
FI941850A0 (fi) Uusi yhdiste, joka on leustroduksiini H, sen valmistus ja terapeuttinen käyttö
IT1245631B (it) Impiego di composti macrolidi come agenti anti-infiammatori per il trattamento di malattie provocate da cessione di istamina

Legal Events

Date Code Title Description
MK1K Patent expired